MedTrace Logo

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

NCT04409223 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2024-02-09

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy and safety of famitinib in the treatment of advanced gastrointestinal stromal tumour patients after failure of imatinib compared to sunitinib.

Conditions

Interventions

DRUG

Famitinib capsules

Oral KIT/PDGFRA kinase inhibitor

DRUG

Sunitinib Capsules

Oral receptor tyrosine kinase (RTK) inhibitor

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jianming Xu, MD · Beijing 302 Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-12
Primary Completion
2022-03-25
Completion
2022-03-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04409223 on ClinicalTrials.gov